A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension
Status:
Completed
Trial end date:
2009-07-02
Target enrollment:
Participant gender:
Summary
This study was a proof-of-efficacy, dose finding study of LCI699 in participants with
mild-to-moderate uncomplicated essential hypertension in order to assess the blood pressure
(BP) lowering effect, safety and tolerability of LCI699 as compared to placebo and
eplerenone.